Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Inoviq Ltd ( (AU:IIQ) ) has shared an announcement.
INOVIQ Ltd has announced the publication of proof-of-concept data demonstrating the efficacy of its engineered CAR-T-exosomes in killing cancer cells and the scalability of its EXO-ACE manufacturing platform. The study, published in the Journal of Visualized Experiments, highlights the potential of INOVIQ’s CAR-exosome therapies to transform cancer treatment by offering a cell-free approach to target and destroy solid tumors, with potential advantages in safety, efficacy, and cost over traditional cell therapies.
The most recent analyst rating on (AU:IIQ) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Inoviq Ltd stock, see the AU:IIQ Stock Forecast page.
More about Inoviq Ltd
INOVIQ Ltd is a leader in exosome technology, advancing next-generation diagnostics and therapeutics aimed at transforming cancer care. The company’s product portfolio includes commercial-stage exosome isolation products, clinical-stage diagnostics for ovarian and breast cancers, and a preclinical CAR-exosome therapeutic program for solid tumors.
Average Trading Volume: 107,640
Technical Sentiment Signal: Sell
Current Market Cap: A$45.77M
For detailed information about IIQ stock, go to TipRanks’ Stock Analysis page.